Foundation for Angelman Syndrome Therapeutics UK

The Foundation for Angelman Syndrome Therapeutics UK (FAST UK) is a registered UK charity (charity number 1167984) dedicated to advancing research and raising awareness for Angelman syndrome, a rare genetic neurological disorder characterized by severe developmental delay, speech impairment, and problems with movement and balance. The foundation's primary goal is to find a cure for Angelman syndrome by supporting scientific research and fostering collaboration among experts.

Mission and Activities

FAST UK focuses on funding and promoting research aimed at understanding Angelman syndrome and developing effective therapies. The charity has established a clear research agenda and assembled a multidisciplinary team of over two dozen scientists from leading universities and pharmaceutical companies to work toward a cure. The organization operates exclusively within the UK but collaborates closely with international counterparts in the United States, Australia, Canada, Italy, and France to maximize research impact.

Fundraising and Financial Information

The foundation raises funds primarily through donations and fundraising activities. For the financial year ending 31 December 2023, FAST UK reported a total income of £267,648, with expenditures amounting to £13,076. All trustee roles are voluntary, with no remuneration or benefits paid to any trustees.

Governance

FAST UK is governed by a board of six trustees who oversee the charity's operations, ensuring transparency and alignment with its mission. The charity does not have subsidiaries and employs no staff earning over £60,000, reflecting its focused and lean organizational structure.

Collaboration and Impact

By uniting researchers, healthcare professionals, families, and advocates, FAST UK plays a crucial role in driving progress toward innovative treatments for Angelman syndrome. The foundation's commitment to collaboration and scientific excellence contributes significantly to the global effort to improve the lives of individuals affected by this condition.

This article summarizes publicly available information on the Foundation for Angelman Syndrome Therapeutics UK as of 2025.

[1] https://cureangelman.org.uk [2] https://register-of-charities.charitycommission.gov.uk/charity-details/?regid=1167984&subid=0 [3] https://www.angelmanuk.org [4] https://cureangelman.org [5] https://www.angelmanuk.org/fundraising-events/